Abstract：
PANoptosis is a unique innate immune inflammatory lytic cell death pathway initiated by an innate immune sensor and driven by caspases and RIPKs. As a distinct pathway, the execution of PANoptosis cannot be hindered by targeting other cell death pathways, such as pyroptosis, apoptosis, or necroptosis. Instead, targeting key PANoptosome components can serve as a strategy to prevent this form of cell death. Given the physiological relevance in several diseases, PANoptosis is a pivotal therapeutic target. Notably, previous research has primarily focused on the role of PANoptosis in cancer and infectious and inflammatory diseases. By contrast, its role in cardiovascular diseases has not been comprehensively discussed. Here, we review the available evidence on PANoptosis in cardiovascular diseases, including cardiomyopathy, atherosclerosis, myocardial infarction, myocarditis, and aortic aneurysm and dissection, and explore a variety of agents that target PANoptosis, with the overarching goal of providing a novel complementary approach to combatting cardiovascular diseases.
摘要：
PANoptosis是由先天性免疫传感器启动并由胱天蛋白酶和RIPK驱动的独特的先天性免疫炎性溶解细胞死亡途径。作为一条独特的途径，PANoptosis的执行不能通过靶向其他细胞死亡途径来阻碍，比如焦亡，凋亡，或坏死。相反，靶向关键的PANoposome组件可以作为防止这种形式的细胞死亡的策略。考虑到几种疾病的生理相关性，PANoptosis是一个关键的治疗靶点。值得注意的是,以前的研究主要集中在PANoptosis在癌症和感染性和炎症性疾病中的作用。相比之下,其在心血管疾病中的作用尚未得到全面讨论。这里,我们回顾了关于心血管疾病中PANoptosis的现有证据，包括心肌病,动脉粥样硬化,心肌梗塞,心肌炎,主动脉瘤和夹层，并探索各种靶向性全景的药物，其总体目标是提供一种新的补充方法来对抗心血管疾病。
